CoChat
Sign Up
Cited by 904

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Wang, Jiang-Hui, Gessler, Dominic J., Zhan, Wei, Gallagher, Thomas L., Gao, Guangping·2024·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-024-01780-wPMC PMC10987683
Open this paper in CoChat — free account

Abstract

Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been engineered for enhanced specificity and developed as a tool for treating various diseases. However, as rAAV is being more widely used as a therapy, the increased demand has created challenges for the existing manufacturing methods. Seven rAAV-based gene therapy products have received regulatory approval, but there continue to be concerns about safely using high-dose viral therapies in humans, including immune responses and adverse effects such as genotoxicity, hepatotoxicity, thrombotic microangiopathy, and neurotoxicity. In this review, we explore AAV biology with an emphasis on current vector engineering strategies and manufacturing technologies. We discuss how rAAVs are being employed in ongoing clinical trials for ocular, neurological, metabolic, hematological, neuromuscular, and cardiovascular diseases as well as cancers. We outline immune responses triggered by rAAV, address associated side effects, and discuss strategies to mitigate these reactions. We hope that discussing recent advancements and current challenges in the field will be a helpful guide for researchers and clinicians navigating the ever-evolving landscape of rAAV-based gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01780-w

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 395

  1. Wang, D. & Gao, G. State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov. Med. 18, 151–161 (2014).
  2. Wang, J. et al. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature 604, 343–348 (2022). · DOI
  3. Wang, D. & Gao, G. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov. Med. 18, 67–77 (2014).
  4. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Sig. Transduct. Target. Ther. 6, 53 (2021). · DOI · Paper page
  5. Atchison, R. W., Casto, B. C. & Hammon, W. M. Adenovirus-associated defective virus particles. Science 149, 754–756 (1965). · DOI · Paper page
  6. Hoggan, M. D., Blacklow, N. R. & Rowe, W. P. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc. Natl Acad. Sci. 55, 1467–1474 (1966). · DOI
  7. Samulski, R. J., Berns, K. I., Tan, M. & Muzyczka, N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl Acad. Sci. 79, 2077–2081 (1982). · DOI · Paper page
  8. Srivastava, A., Lusby, E. W. & Berns, K. I. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555–564 (1983). · DOI · Paper page
  9. Samulski, R. J., Chang, L. S. & Shenk, T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61, 3096–3101 (1987). · DOI
  10. Gao, G. P. et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. 99, 11854–11859 (2002). · DOI · Paper page
  11. Gao, G. et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381–6388 (2004). · DOI · Paper page
  12. Cheung, A. K., Hoggan, M. D., Hauswirth, W. W. & Berns, K. I. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J. Virol. 33, 739–748 (1980). · DOI
  13. Laughlin, C. A., Cardellichio, C. B. & Coon, H. C. Latent infection of KB cells with adeno-associated virus type 2. J. Virol. 60, 515–524 (1986). · DOI
  14. Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019). · DOI · Paper page
  15. Keeler, A. M. & Flotte, T. R. Recombinant adeno-associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu. Rev. Virol. 6, 601–621 (2019). · DOI · Paper page
  16. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020). · DOI
  17. Tseng, Y. S. & Agbandje-McKenna, M. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front. Immunol. 5, 9 (2014). · DOI
  18. Sonntag, F., Schmidt, K. & Kleinschmidt, J. A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. 107, 10220–10225 (2010). · DOI · Paper page
  19. Kelsic, E. D., Ogden, P. J., Sinai, S. & Church, G. M. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science 366, 1139–1143 (2019). · DOI · Paper page
  20. Lusby, E., Fife, K. H. & Berns, K. I. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J. Virol. 34, 402–409 (1980). · DOI
  21. Gao, G. et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl Acad. Sci. 100, 6081–6086 (2003). · DOI
  22. Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381–390 (2009). · DOI · Paper page
  23. Bashirians, G. et al. Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy. Blood 140, 10668–10670 (2022). · DOI
  24. Matsushita, T. et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938–945 (1998). · DOI
  25. Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224–2232 (1998). · DOI · Paper page
  26. McCarty, D. M. Jr., Young, S. M. & Samulski, R. J. Integration of adeno-associated viruS (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38, 819–845 (2004). · DOI · Paper page
  27. Servellita, V. et al. Adeno-associated virus type 2 in US children with acute severe hepatitis. Nature 617, 1–7 (2023). · DOI
  28. Morfopoulou, S. et al. Genomic investigations of unexplained acute hepatitis in children. Nature 617, 564–573 (2023). · DOI
  29. Ho, A. et al. Adeno-associated virus 2 infection in children with non-A–E hepatitis. Nature 617, 555–563 (2023). · DOI
  30. Tacke, F. Severe hepatitis outbreak in children linked to AAV2 virus. Nature 617, 471–472 (2023). · DOI
  31. Lisowski, L., Tay, S. S. & Alexander, I. E. Adeno-associated virus serotypes for gene therapeutics. Curr. Opin. Pharmacol. 24, 59–67 (2015). · DOI
  32. Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V. & Rizvanov, A. A. Various AAV Serotypes and their applications in gene therapy: an overview. Cells 12, 785 (2023). · DOI
  33. Verdera, H. C., Kuranda, K. & Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723–746 (2020). · DOI · Paper page
  34. Pillay, S. et al. Adeno-associated Virus (AAV) serotypes have distinctive interactions with domains of the cellular AAV receptor. J. Virol. 91, e00391–17 (2017). · DOI
  35. Dudek, A. M. et al. GPR108 is a highly conserved AAV entry factor. Mol. Ther. 28, 367–381 (2020). · DOI
  36. Woodard, K. T., Liang, K. J., Bennett, W. C. & Samulski, R. J. Heparan sulfate binding promotes accumulation of intravitreally delivered adeno-associated viral vectors at the retina for enhanced transduction but weakly influences tropism. J. Virol. 90, 9878–9888 (2016). · DOI · Paper page
  37. Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H. & Asokan, A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286, 13532–13540 (2011). · DOI
  38. Dudek, A. M. et al. An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor. J. Virol. 92, e02213–e02217 (2018). · DOI
  39. Berry, G. E. & Asokan, A. Cellular transduction mechanisms of adeno-associated viral vectors. Curr. Opin. Virol. 21, 54–60 (2016). · DOI
  40. Schultz, B. R. & Chamberlain, J. S. Recombinant adeno-associated virus transduction and integration. Mol. Ther. 16, 1189–1199 (2008). · DOI
  41. Sonntag, F., Bleker, S., Leuchs, B., Fischer, R. & Kleinschmidt, J. A. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80, 11040–11054 (2006). · DOI
  42. Xiao, P. J. & Samulski, R. J. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J. Virol. 86, 10462–10473 (2012). · DOI
  43. Nicolson, S. C. & Samulski, R. J. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J. Virol. 88, 4132–4144 (2014). · DOI
  44. Kelich, J. M. et al. Super-resolution imaging of nuclear import of adeno-associated virus in live cells. Mol. Ther. Methods Clin. Dev. 2, 15047 (2015). · DOI
  45. Fisher, K. J. et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70, 520–532 (1996). · DOI
  46. McCarty, D. M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 16, 1648–1656 (2008). · DOI · Paper page
  47. McCarty, D. M. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112–2118 (2003). · DOI · Paper page
  48. Wang, Z. et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105–2111 (2003). · DOI · Paper page
  49. Zinn, E. et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 12, 1056–1068 (2015). · DOI · Paper page
  50. Lochrie, M. A. et al. Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. Virology 353, 68–82 (2006). · DOI
  51. Arbetman, A. E. et al. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J. Virol. 79, 15238–15245 (2005). · DOI
  52. Bossis, I. & Chiorini, J. A. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles. J. Virol. 77, 6799–6810 (2003). · DOI
  53. Mietzsch, M. et al. Characterization of the serpentine adeno-associated virus (SAAV) capsid structure: receptor interactions and antigenicity. J. Virol. 96, e00335–22 (2022). · DOI
  54. Zhong, L. et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194–202 (2008). · DOI · Paper page
  55. Zhong, L. et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol. Ther. 15, 1323–1330 (2007). · DOI
  56. Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. 105, 7827–7832 (2008). · DOI · Paper page
  57. Kanaan, N. M. et al. Rationally engineered AAV capsids improve transduction and volumetric spread in the CNS. Mol. Ther. Nucleic Acids 8, 184–197 (2017). · DOI
  58. Wang, D. et al. A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates. Mol. Ther. Methods Clin. Dev. 9, 234–246 (2018). · DOI
  59. Shi, W., Arnold, G. S. & Bartlett, J. S. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of aav2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711 (2001). · DOI
  60. Yao, Y. et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates. Nat. Biomed. Eng. 6, 1257–1271 (2022). · DOI · Paper page
  61. Tse, L. V. et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc. Natl Acad. Sci. 114, E4812–E4821 (2017). · DOI · Paper page
  62. Shen, X., Storm, T. & Kay, M. A. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol. Ther. 15, 1955–1962 (2007). · DOI
  63. Andrzejewski, S., Karan, K. R., Stiles, K. M., Hackett, N. R. & Crysta, R. G. Engineering of the AAVrh.10 capsid for cardiac gene transfer (ASGCT abstract 1389). Mol. Ther. 31, S1–794 (2023).
  64. Croyle, M. A. et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 12, 579–587 (2005). · DOI
  65. Samai, Poulami et al. Antibody conjugated AAV vectors for efficient and specific skeletal muscle directed gene delivery across species (ASGCT abstract 42). Mol. Ther. 31, S1–794 (2023).
  66. Hong, A. V., Seul-Petat, L., Hierves, A. A., Poupiot, J. & Richard, I. An integrin-targeting AAV developed by a novel computational rational design methodology presents an improved targeting to the skeletal muscle and reduced tropism to the liver (ASGCT abstract 332). Mol. Ther. 31, S1–794 (2023).
  67. Chin, J. W. Expanding and reprogramming the genetic code. Nature 550, 53–60 (2017). · DOI
  68. Puzzo, F. et al. Aptamer-programmable adeno-associated viral vectors as a novel platform for cell-specific gene transfer. Mol. Ther. Nucleic Acids 31, 383–397 (2023). · DOI
  69. Chang, H. et al. Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice. Mol. Ther. Methods Clin. Dev. 31, 101129 (2023). · DOI
  70. Koerber, J. T., Jang, J. H. & Schaffer, D. V. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16, 1703–1709 (2008). · DOI · Paper page
  71. Havlik, L. P. et al. Coevolution of adeno-associated virus capsid antigenicity and tropism through a structure-guided approach. J. Virol. 94, e00976–20 (2020). · DOI
  72. Liguore, W. A. et al. AAV-PHP.B Administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice. Mol. Ther. 27, 2018–2037 (2019). · DOI
  73. Moyer, Tyler et al. Directed evolution of an AAV9 library identifies a capsid variant with enhanced brain tropism and liver de-targeting in non-human primates and mice following systemic administration [ASGCT abstract 105]. Mol. Ther. 31, S1–794 (2023).
  74. Maura, D. et al. Stepwise evolution of the AAV5-derived capsid VCAP-100 identifies novel variants with improved CNS transduction and liver detargeting following systemic injection (ASGCT abstract 464). Mol. Ther. 31, S1–794 (2023).
  75. Tabebordbar, M. et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919–4938.e22 (2021). · DOI
  76. Jin, Q. et al. Discovery of novel AAV capsids with enhanced skeletal muscle tropism following directed evolution in cynomolgus macaque (ASGCT abstract 1165). Mol. Ther. 31, S1–794 (2023).
  77. Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182–188 (2018). · DOI · Paper page
  78. Gonzalez, T. J. et al. Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nat. Commun. 13, 5947 (2022). · DOI · Paper page
  79. Andres-Mateos, E. et al. Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate. Nat. Commun. 13, 1359 (2022). · DOI
  80. Libbrecht, M. W. & Noble, W. S. Machine learning applications in genetics and genomics. Nat. Rev. Genet. 16, 321–332 (2015). · DOI
  81. Park, C., Took, C. C. & Seong, J. K. Machine learning in biomedical engineering. Biomed. Eng. Lett. 8, 1–3 (2018). · DOI
  82. Bryant, D. H. et al. Deep diversification of an AAV capsid protein by machine learning. Nat. Biotechnol. 39, 691–696 (2021). · DOI
  83. Xie, J. et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 19, 526–535 (2011). · DOI
  84. Young, S. M. Jr & Samulski, R. J. Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc. Natl Acad. Sci. 98, 13525–13530 (2001). · DOI
  85. Bell, P. et al. Effects of self-complementarity, codon optimization, transgene, and dose on liver transduction with AAV8. Hum. Gene Ther. Methods 27, 228–237 (2016). · DOI · Paper page
  86. Fu, H. et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8, 911–917 (2003). · DOI
  87. Gao, G. P. et al. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J. Virol. 80, 6192–6194 (2006). · DOI
  88. Korolev, S. E., Solov’ev, V. V. & Tumanian, V. G. A new method of global search for functional DNA segments using a fractal representation of nucleotide texts. Biofizika 37, 837–847 (1992).
  89. Martino, A. T. et al. The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver. Blood 117, 6459–6468 (2011). · DOI · Paper page
  90. Pan, X. et al. Rational engineering of a functional CpG-free ITR for AAV gene therapy. Gene Ther. 29, 333–345 (2022). · DOI · Paper page
  91. Xie, Q. et al. Endogenous human SMN1 promoter- driven gene replacement improves the efficacy and safety of AAV9-mediated gene therapy for spinal muscular atrophy (SMA) in mice (ASGCT abstract 263). Mol. Ther. 30, S1–592 (2022).
  92. Gray, S. J. et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143–1153 (2011). · DOI · Paper page
  93. Zheng, D. et al. Machine-guided design of tissue-specific promoters (Abstract 172). Mol. Ther. 31, S1–794 (2023).
  94. Ye, X. et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283, 88–91 (1999). · DOI
  95. Rivera, V. M. et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105, 1424–1430 (2005). · DOI
  96. Breaker, R. R. Riboswitches and the RNA world. Cold Spring Harb. Perspect. Biol. 4, a003566 (2012). · DOI
  97. Zhong, G. et al. A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo. Nat. Biotechnol. 38, 169–175 (2020). · DOI
  98. Zhong, G., Wang, H., Bailey, C. C., Gao, G. & Farzan, M. Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells. eLife 5, e18858 (2016). · DOI
  99. Luo, L., Jea, J. D.-Y., Wang, Y., Chao, P.-W. & Yen, L. Control of mammalian gene expression by modulation of polyA signal cleavage at 5′ UTR. Nat. Biotechnol. 1–13 https://doi.org/10.1038/s41587-023-01989-0. (2024) · DOI
  100. Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291–295 (2021). · DOI
  101. Naruse, C. et al. A degron system targeting endogenous PD-1 inhibits the growth of tumor cells in mice. NAR Cancer 4, zcac019 (2022). · DOI
  102. Brown, H. C. et al. Target-cell-directed bioengineering approaches for gene therapy of hemophilia A. Mol. Ther. Methods Clin. Dev. 9, 57–69 (2018). · DOI
  103. Ward, N. J. et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 117, 798–807 (2011). · DOI
  104. Steines, B. et al. CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes. JCI Insight 1, e88728 (2016). · DOI
  105. Gessler, D. J. et al. Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease. JCI Insight 2, e90807 (2017). · DOI · Paper page
  106. Konkle, B. A. et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood 137, 763–774 (2020). · DOI · Paper page
  107. Ravi, S., Sharma, T., Yip, M., Gao, G. & Tai, P. W. L. Improving codon optimization for gene therapy vectors using deep learning (ASGCT abstract 173). Mol. Ther. 31, S1–794 (2023).
  108. Powell, S. K., Rivera-Soto, R. & Gray, S. J. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov. Med. 19, 49–57 (2015).
  109. Patricio, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E. & MacLaren, R. E. Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina. Mol. Ther. Nucleic Acids 6, 198–208 (2017). · DOI
  110. Themis, M. et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 12, 763–771 (2005). · DOI · Paper page
  111. Miao, C. H. et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol. Ther. 1, 522–532 (2000). · DOI
  112. Lu, J. et al. A 5’ noncoding exon containing engineered intron enhances transgene expression from recombinant AAV vectors in vivo. Hum. Gene Ther. 28, 125–134 (2017). · DOI · Paper page
  113. Muhuri, M. et al. Novel combinatorial microRNA-binding sites in AAV Vectors synergistically diminish antigen presentation and transgene immunity for efficient and stable transduction. Front. Immunol. 12, 674242 (2021). · DOI · Paper page
  114. Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567–575.e5 (2019). · DOI
  115. Maeder, M. L. et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 25, 229–233 (2019). · DOI · Paper page
  116. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019). · DOI · Paper page
  117. Komor, A. C. et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci. Adv. 3, eaao4774 (2017). · DOI · Paper page
  118. Lai, Y. et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435–1439 (2005). · DOI · Paper page
  119. Nakai, H., Storm, T. A. & Kay, M. A. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 18, 527–532 (2000). · DOI · Paper page
  120. Sun, L., Li, J. & Xiao, X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6, 599–602 (2000). · DOI · Paper page
  121. Pergolizzi, R. G. et al. In vivo trans-splicing of 5′ and 3′ segments of Pre-mRNA directed by corresponding DNA sequences delivered by gene transfer. Mol. Ther. 8, 999–1008 (2003). · DOI
  122. Song, Y. et al. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. Hum. Gene Ther. 20, 267–281 (2009). · DOI
  123. Riedmayr, L. M. et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat. Commun. 14, 6578 (2023). · DOI
  124. Li, J., Sun, W., Wang, B., Xiao, X. & Liu, X.-Q. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum. Gene Ther. 19, 958–964 (2008). · DOI
  125. Chew, W. L. et al. A multifunctional AAV–CRISPR–Cas9 and its host response. Nat. Methods 13, 868–874 (2016). · DOI · Paper page
  126. Truong, D.-J. J. et al. Development of an intein-mediated split–Cas9 system for gene therapy. Nucleic Acids Res. 43, 6450–6458 (2015). · DOI · Paper page
  127. Villiger, L. et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat. Med. 24, 1519–1525 (2018). · DOI
  128. Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97–110 (2020). · DOI
  129. Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 1–12 https://doi.org/10.1038/s41587-023-01758-z (2023). · DOI
  130. Tornabene, P. et al. Inclusion of a degron reduces levels of undesired inteins after AAV-mediated protein trans-splicing in the retina. Mol. Ther. Methods Clin. Dev. 23, 448–459 (2021). · DOI · Paper page
  131. Su, W. et al. Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination. Nat. Commun. 13, 1182 (2022). · DOI
  132. Sena-Esteves, M. & Gao, G. Purification of recombinant adeno-associated viruses (rAAVs) by Iodixanol gradient centrifugation. Cold Spring Harb. Protoc. 2020, 095612 (2020). · DOI
  133. Sena-Esteves, M. & Gao, G. Introducing genes into mammalian cells: viral vectors. Cold Spring Harb. Protoc. 2020, 095513 (2020). pdb.top095513. · DOI
  134. Su, Q., Sena-Esteves, M. & Gao, G. Purification of recombinant adeno-associated viruses (rAAVs) by cesium chloride gradient sedimentation. Cold Spring Harb. Protoc. 2020, 095604 (2020).
  135. Naso, M. F., Tomkowicz, B., Perry, W. L. & Strohl, W. R. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317–334 (2017). · DOI · Paper page
  136. Louis, N., Evelegh, C. & Graham, F. L. Cloning and sequencing of the cellular–viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233, 423–429 (1997). · DOI
  137. Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–72 (1977). · DOI · Paper page
  138. Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J. A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745–2760 (1998). · DOI
  139. Tang, Q. et al. Two-plasmid packaging system for recombinant adeno-associated virus. BioResearch Open Access 9, 219–228 (2020). · DOI
  140. Hakim, C. H. et al. Micro-dystrophin AAV vectors made by transient transfection and herpesvirus system are equally potent in treating mdx mouse muscle disease. Mol. Ther. Methods Clin. Dev. 18, 664–678 (2020). · DOI
  141. Liu, H. et al. A modified triple transfection method produces high-quality AAV vectors with much-reduced plasmid demand (ASGCT abstract 48). Mol. Ther. 31, S1–794 (2023).
  142. Wang, Q. et al. AAVone: an all-in-one plasmid system for efficient AAv production (ASGCT abstract 829). Mol. Ther. 31, S1–794 (2023).
  143. Yla-Herttuala, S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 20, 1831–1832 (2012). · DOI
  144. Urabe, M., Ding, C. & Kotin, R. M. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13, 1935–1943 (2002). · DOI
  145. Becerra, S. P., Koczot, F., Fabisch, P. & Rose, J. A. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 62, 2745–2754 (1988). · DOI
  146. Kondratov, O. et al. Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells. Mol. Ther. 25, 2661–2675 (2017). · DOI
  147. Aslanidi, G., Lamb, K. & Zolotukhin, S. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc. Natl Acad. Sci. 106, 5059–5064 (2009). · DOI
  148. Moreno, F., Lip, F., Rojas, H. & Anggakusuma, Development of an insect cell-based adeno-associated virus packaging cell line employing advanced Rep gene expression control system. Mol. Ther. Methods Clin. Dev. 27, 391–403 (2022). · DOI
  149. Airenne, K. J. et al. Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol. Ther. 21, 739–749 (2013). · DOI
  150. Kohlbrenner, E. et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 12, 1217–1225 (2005). · DOI
  151. Pijlman, G. P., Vrij, J., de, End, F. J., van den, Vlak, J. M. & Martens, D. E. Evaluation of baculovirus expression vectors with enhanced stability in continuous cascaded insect-cell bioreactors. Biotechnol. Bioeng. 87, 743–753 (2004). · DOI
  152. Pijlman, G. P. et al. Relocation of the attTn7 transgene insertion site in bacmid DNA enhances baculovirus genome stability and recombinant protein expression in insect cells. Viruses 12, 1448 (2020). · DOI
  153. Chen, H. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol. Ther. 16, 924–930 (2008). · DOI
  154. Liu, S. et al. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol. Ther. 32, 74–83 (2024). · DOI
  155. Loo, J. Cvander & Wright, J. F. Progress and challenges in viral vector manufacturing. Hum. Mol. Genet. 25, R42–R52 (2016). · DOI
  156. Yuan, Z., Qiao, C., Hu, P., Li, J. & Xiao, X. A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes. Hum. Gene Ther. 22, 613–624 (2011). · DOI
  157. Zhang, H., Xie, J., Xie, Q., Wilson, J. M. & Gao, G. Adenovirus–adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum. Gene Ther. 20, 922–929 (2009). · DOI
  158. Gao, G. P. et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9, 2353–2362 (1998). · DOI
  159. Clark, K. R., Voulgaropoulou, F., Fraley, D. M. & Johnson, P. R. Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6, 1329–1341 (1995). · DOI
  160. Farson, D. et al. Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectors. J. Gene Med. 6, 1369–1381 (2004). · DOI
  161. Jalšić, L. et al. Inducible HEK293 AAV packaging cell lines expressing Rep proteins. Mol. Ther. Methods Clin. Dev. 30, 259–275 (2023). · DOI
  162. Martin, J. et al. Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum. Gene Ther. Methods 24, 253–269 (2013). · DOI
  163. Gao, G. P. et al. Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 5, 644–649 (2002). · DOI
  164. Conway, J. E. et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther. 6, 986–993 (1999). · DOI
  165. Conway, J. E., Zolotukhin, S., Muzyczka, N., Hayward, G. S. & Byrne, B. J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71, 8780–8789 (1997). · DOI
  166. Flotte, T. R. et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum. Gene Ther. 22, 1239–1247 (2011). · DOI · Paper page
  167. Thorne, B. A., Takeya, R. K. & Peluso, R. W. Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene Ther. 20, 707–714 (2009). · DOI
  168. Zhang, H.-G. et al. Recombinant adenovirus expressing adeno-associated virus cap and rep proteins supports production of high-titer recombinant adeno-associated virus. Gene Ther. 8, 704–712 (2001). · DOI
  169. Nguyen, T. N. T. et al. Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells. Mol. Ther. Methods Clin. Dev. 21, 642–655 (2021). · DOI · Paper page
  170. Leong, J. Titer boosting of HEK293-based aav manufacturing process using proprietary small molecule additive and successful scale up to 200L (ASGCT abstract 407). Mol. Ther. 31, S1–794 (2023).
  171. Sutherland, K. et al. Development and scale-up validation of small molecule enhancers for increased viral vector yield (ASGCT abstract 425). Mol. Ther. 31, S1–794 (2023).
  172. Dietrich, N., Lasater, S., Rabinowitz, J. & Israel, J. Analysis of mechanisms driving improved adeno-associated vector production by the addition of small molecules (ASGCT abstract 47). Mol. Ther. 31, S1–794 (2023).
  173. Barnes, C. R. et al. Genome-wide activation screens to increase adeno-associated virus production. Mol. Ther. Nucleic Acids 26, 94–103 (2021). · DOI
  174. Maurer, A. C. et al. Genome-wide CRISPR screen in HEK293 identifies putative cellular restriction factors for AAV manufacturing (ASGCT abstract 965). Mol. Ther. 28, S1–592 (2020).
  175. Chung, C.-H. et al. Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cells. Mol. Ther. Methods Clin. Dev. 28, 272–283 (2023). · DOI
  176. Mietzsch, M. et al. Improved genome packaging efficiency of adeno-associated virus vectors using rep hybrids. J. Virol. 95, e00773–21 (2021). · DOI
  177. Andari, J. E. & Grimm, D. Production, processing, and characterization of synthetic AAV gene therapy vectors. Biotechnol. J. 16, e2000025 (2021). · DOI
  178. Fekete, S. et al. Chromatographic strategies for the analytical characterization of adeno-associated virus vector-based gene therapy products. TrAC Trends Anal. Chem. 164, 117088 (2023). · DOI
  179. Lee, Z., Lu, M., Irfanullah, E., Soukup, M. & Hu, W.-S. Construction of an rAAV Producer Cell Line through Synthetic Biology. ACS Synth. Biol. 11, 3285–3295 (2022). · DOI
  180. Lu, M. et al. Enhancing the production of recombinant adeno‐associated virus in synthetic cell lines through systematic characterization. Biotechnol. Bioeng. 121, 341–354 (2024). · DOI
  181. Coronel, J. et al. Efficient production of rAAV in a perfusion bioreactor using an ELEVECTA® stable producer cell line. Genet. Eng. Biotechnol. News 41, S23 (2021). · DOI
  182. Tai, P. W. L. et al. Adeno-associated virus genome population sequencing achieves full vector genome resolution and reveals human-vector chimeras. Mol. Ther. Methods Clin. Dev. 9, 130–141 (2018). · DOI · Paper page
  183. Earley, L. F. et al. Long read sequencing of rAAV vectors illuminates origins of contaminating genomic species (ASGCT abstract 178). Mol. Ther. 31, S1–794 (2023).
  184. Tran, N. T. et al. AAV-genome population sequencing of vectors packaging CRISPR components reveals design-influenced heterogeneity. Mol. Ther. Methods Clin. Dev. 18, 639–651 (2020). · DOI
  185. Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860 (2017). · DOI · Paper page
  186. Megaw, R. D., Soares, D. C. & Wright, A. F. RPGR: its role in photoreceptor physiology, human disease, and future therapies. Exp. Eye Res. 138, 32–41 (2015). · DOI
  187. Cehajic-Kapetanovic, J. et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat. Med. 26, 354–359 (2020). · DOI · Paper page
  188. Camara, C. M.-F. D. L., Cehajic-Kapetanovic, J. & MacLaren, R. E. RPGR gene therapy presents challenges in cloning the coding sequence. Expert Opin. Biol. Ther. 20, 63–71 (2020). · DOI
  189. Cideciyan, A. V. et al. Progression in X-linked retinitis pigmentosa due to ORF15-RPGR mutations: assessment of localized vision changes over 2 years. Investig. Opthalmol. Vis. Sci. 59, 4558–4566 (2018). · DOI
  190. Krusenstiern, Lvon et al. Changes in retinal sensitivity associated with Cotoretigene Toliparvovec in X-linked retinitis pigmentosa with RPGR gene variations. JAMA Ophthalmol. 141, 275–283 (2023). · DOI
  191. Massengill, M. T. & Lewin, A. S. Gene therapy for rhodopsin-associated autosomal dominant retinitis pigmentosa. Int. Ophthalmol. Clin. 61, 79–96 (2021). · DOI
  192. Philippidis, A. In through the out door: editas’ CEOs grasp opportunities amidst challenges. GEN Biotechnol. 1, 215–217 (2022). · DOI
  193. Liao, D. et al. Optogenetic therapy with MCO-010 for vision restoration in patients with severe sight loss due to retinitis pigmentosa: the phase 2b RESTORE Study (ASGCT abstract 808). Mol. Ther. 31, S1–794 (2023).
  194. Lukason, M. et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol. Ther. 19, 260–265 (2011). · DOI
  195. Constable, I. J. et al. Phase 2a randomized clinical trial: safety and post Hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 14, 168–175 (2016). · DOI · Paper page
  196. Constable, I. J. et al. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am. J. Ophthalmol. 177, 150–158 (2017). · DOI · Paper page
  197. Heier, J. S. et al. Safety and efficacy of subretinally administered palucorcel for geographic atrophy of age-related macular degeneration: phase 2b study. Ophthalmol. Retin. 4, 384–393 (2020). · DOI · Paper page
  198. Khanani, A. M., Kiss, S., Turpcu, A., Hoang, C. & Osborne, A. Phase 1 study of intravitreal gene therapy ADVM-022 for neovascular AMD (OPTIC Trial). Investig. Ophthalmol. Vis. Sci. 61, 1154–1154 (2020).
  199. Hwu, W.-L., Chien, Y.-H., Lee, N.-C. & Li, M.-H. Natural history of aromatic l-amino acid decarboxylase deficiency in Taiwan. JIMD Rep. 40, 1–6 (2017). · DOI
  200. Wassenberg, T. et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J. Rare Dis. 12, 12 (2017). · DOI

200 of 395 shown

Cited by

Sorted by citations

Metadata

Authors
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G.
ORCID
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2024-04-03
Volume
9
Issue
1
ISSN
2059-3635
DOI
10.1038/s41392-024-01780-w
PMC
PMC10987683
Cited by
904
References
91
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review